Barclays has increased its price target for Quest Diagnostics (DGX, Financial) from $175 to $185, while maintaining an Equal Weight rating on the stock. The company’s first-quarter performance has been described as robust, positioning Quest Diagnostics as a reliable investment option during uncertain times, according to an analyst's insights shared with investors.
Furthermore, Barclays expresses confidence in Quest Diagnostics' current guidance, suggesting it is not only attainable but potentially surpassable, indicating optimism about the company's future performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for Quest Diagnostics Inc (DGX, Financial) is $183.22 with a high estimate of $198.00 and a low estimate of $160.00. The average target implies an upside of 6.01% from the current price of $172.84. More detailed estimate data can be found on the Quest Diagnostics Inc (DGX) Forecast page.
Based on the consensus recommendation from 20 brokerage firms, Quest Diagnostics Inc's (DGX, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Quest Diagnostics Inc (DGX, Financial) in one year is $156.78, suggesting a downside of 9.29% from the current price of $172.84. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Quest Diagnostics Inc (DGX) Summary page.
